Hanmi Pharm Strikes Up to $2.3 Billion Licensing Deal With Genentech for Muscle‑Sparing Obesity Candidate HM17321
Hanmi Pharm. Co., Ltd. announced it has entered into an exclusive licensing agreement with Genentech,...
Hanmi Pharmaceutical
Hanmi Pharm Secures $1.26 Billion Deal with Eli Lilly for GLP-2 Analog Sonefpeglutide in Global Licensing Agreement
Hanmi Pharm. Co., Ltd. (“Hanmi”) announced a strategic global licensing agreement with Eli Lilly (NYSE:...
Hanmi Pharmaceutical Partners with Chongqing Zhongfu – Amlodipine/Losartan Fixed-Dose Combo Targets China Out-of-Hospital Digital Market
Hanmi Pharmaceutical (South Korea) announced a partnership with Chongqing Zhongfu Pharmaceutical Co., Ltd. to jointly...
C‑MER Medical, Gilead, and Hanmi Sign Global Licensing Deal for First‑In‑Class P‑glycoprotein Inhibitor Encequidar
C‑MER Medical Holdings Limited (HKG: 3309) announced that its joint‑venture arm, Health Hope Pharma Limited...
E-commerce and Physical Stores to Stock Hanmi’s OTC Drugs Following Shanghai Pharma Deal
Hanmi Pharmaceutical, a leading South Korean pharmaceutical company, has reportedly entered into a supply agreement...
MSD Partners with Hanmi Pharmaceutical to Develop Combination Therapy for Solid Tumors
Merck, Sharp & Dohme (MSD; NYSE: MRK) has announced a partnership with South Korea’s Hanmi...
FDA Rejects Spectrum’s Poziotinib NDA for NSCLC Treatment
US-based Spectrum Pharmaceuticals Inc. (Nasdaq: SPPI) announced last week that its New Drug Application (NDA)...